What contains tirzepatide, and what does that mean for you?

Which product actually contains tirzepatide, and why does that matter?

Many people arrive at this question because they have heard the drug name tirzepatide in the news, on a podcast, or from a friend, and want to know what product to ask about. The answer is straightforward: in the UK, tirzepatide is sold exclusively as Mounjaro. No other licensed UK medicine, supplement, or pharmacy product contains it. If you have seen anything described online as tirzepatide in a different format (a tablet, a vial, a compounded cream) it has no UK marketing authorisation and falls outside the regulated supply chain.

It is also worth clearing up one misconception that circulates fairly widely: some people assume tirzepatide is a type of insulin. It is not. Mounjaro contains no insulin and does not act like one. It mimics two naturally occurring gut hormones (GIP and GLP-1) to reduce appetite and slow the rate at which the stomach empties. The mechanism is quite different from insulin therapy, and Mounjaro does not carry the same hypoglycaemia risks in people without diabetes.

The NHS medicines page for tirzepatide explains the drug's action and approved uses in plain language, and is a reliable starting point if you want to read further. Knowing which product you are asking about matters because Mounjaro's dosing schedule, storage requirements, and clinical suitability criteria are specific to it, they do not transfer across to semaglutide (Wegovy or Ozempic) or other GLP-1 medicines.

What the KwikPen physically contains, and what it does not

The Mounjaro device is a pre-filled, pre-set pen. Each pen holds four weekly doses of tirzepatide dissolved in a clear solution alongside a small number of inactive ingredients (things like water for injection, sodium phosphate, and a preservative) that hold the molecule stable. You can read the full ingredient list in the detailed breakdown of what Mounjaro contains, including the excipients.

Each pen is single-strength: a 5 mg pen, for example, delivers 5 mg with every injection. UK strengths are 2.5, 5, 7.5, 10, 12.5, and 15 mg. Treatment always starts at 2.5 mg (a dose chosen for tolerability rather than therapeutic effect) and a prescriber adjusts the schedule from there, typically in four-week steps. The pen itself is disposable and does not require the user to draw up or measure anything.

Storage is in a fridge at 2–8°C. There is a limited window during which a pen can be kept at room temperature, but the exact duration is specified in the Patient Information Leaflet rather than a figure anyone should quote from memory, because it can depend on circumstances. If you are thinking about whether a weight-loss injection is right for you, storage practicalities are worth raising during your consultation.

How tirzepatide sits within the wider weight-loss medicine landscape

Understanding what contains tirzepatide also means understanding what does not. Semaglutide (found in Wegovy (for weight management) and Ozempic (licensed for type 2 diabetes, not weight loss)) activates only the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors, which is why it is described as a dual agonist. Whether Mounjaro contains GLP-1 activity is a question worth understanding properly, and the short answer is yes, plus an additional pathway.

NICE recommended tirzepatide for NHS use in December 2024 (Technology Appraisal TA1026) for adults with a BMI of 35 or above and at least one weight-related health condition, with lower thresholds applying for some ethnic backgrounds under UK guidance. NHS eligibility is being rolled out in phases, which means many people who would clinically benefit do not yet qualify through the NHS. Private routes, through a pharmacy you can verify on the GPhC register, offer access without a waiting list, subject to the same clinical assessment a prescriber carries out before any prescription.

For a sense of what private treatment costs, the Mounjaro price page sets out the honest context, including why prices shifted significantly after Eli Lilly adjusted UK list prices in September 2025. Cost is one factor in the decision; clinical suitability is another.

What to do with this information

If you have established that tirzepatide in Mounjaro is the medicine you want to explore, the next step is a clinical assessment. That is not a formality, it is how a prescriber checks that the medicine is safe alongside any existing conditions or medications you take, confirms your BMI, and sets the right starting point. More background on what tirzepatide is and how it works may also help you prepare for that conversation.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally, your responses go to a named clinician, not an automated system. Our pharmacy holds GPhC premises registration 9012878, which you can verify directly at the GPhC register. If you have questions before starting, the FAQs cover the most common ones, or you can get in touch with our team directly. When you are ready, you can speak to our prescribers through a free consultation, no obligation, just a proper clinical conversation.